{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:01:46Z","timestamp":1705622506843},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1097\/00000441-200501000-00010","type":"journal-article","created":{"date-parts":[[2005,1,6]],"date-time":"2005-01-06T09:01:47Z","timestamp":1105002107000},"page":"52-53","source":"Crossref","is-referenced-by-count":8,"title":["Ramiprii-induced Agranulocytosis Confirmed by a Lymphocyte Cytotoxicity Test"],"prefix":"10.1016","volume":"329","author":[{"given":"Nathaniel","family":"Horowitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madlen","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yishai","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimon","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/00000441-200501000-00010_bb0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1097\/00000441-200501000-00010_bb0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2165\/00002018-199207010-00004","article-title":"Adverse effects of angiotensin converting enzyme (ACE) inhibitors: an update","volume":"7","author":"Parish","year":"1992","journal-title":"Drug Saf"},{"key":"10.1097\/00000441-200501000-00010_bb0015","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archinte.1992.00400190095018","article-title":"Descriptive epidemiology of agranulocytosis","volume":"152","author":"Strom","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1097\/00000441-200501000-00010_bb0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.1996.tb01641.x","article-title":"Drugs in the aetiology of agranulocytosis and aplastic anaemia","volume":"60","author":"Kaufman","year":"1996","journal-title":"Eur J Haematol Suppl"},{"key":"10.1097\/00000441-200501000-00010_bb0025","first-page":"536","article-title":"Rifampininduced thrombocytopenia: diagnosis by a novel in vitro lymphocyte toxicity assay","volume":"3","author":"Krivoy","year":"2001","journal-title":"Isr Med Assoc J"},{"key":"10.1097\/00000441-200501000-00010_bb0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/clpt.1991.37","article-title":"Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: the International Agranulocytosis and Aplastic Anemia Study","volume":"49","author":"Kelly","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/00000441-200501000-00010_bb0035","series-title":"Williams Hematology","first-page":"810","article-title":"Neutropenia","author":"Dale","year":"1995"},{"key":"10.1097\/00000441-200501000-00010_bb0040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0887-7963(93)70143-1","article-title":"Specificity of drug induced immune cytopenias","volume":"7","author":"Christie","year":"1993","journal-title":"Transfus Med Rev"},{"key":"10.1097\/00000441-200501000-00010_bb0045","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1015934104984","article-title":"Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes","volume":"6","author":"Uetrecht","year":"1989","journal-title":"Pharm Res"},{"key":"10.1097\/00000441-200501000-00010_bb0050","first-page":"274","article-title":"Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells","volume":"245","author":"Uetrecht","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1097\/00000441-200501000-00010_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0609.1994.tb01280.x","article-title":"Drug-induced neutropenia due to direct effects on CFU-C: ten years of culture experience","volume":"52","author":"Irvine","year":"1994","journal-title":"Eur J Haematol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296291533932X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296291533932X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T19:29:44Z","timestamp":1705606184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000296291533932X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S000296291533932X"],"URL":"https:\/\/doi.org\/10.1097\/00000441-200501000-00010","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}